| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1440 | Cj-054 | Polo-like kinase 1 (Plk1) inhibitor |
|
| DCC1441 | Cj-1383 | Novel Cell-Permeable STAT3 Inhibitor, targeting the SH2 domain |
|
| DCC1442 | Cj-15208 | Biological Active Reagents |
|
| DCC1443 | Cj-1882 | Potent and competitive antagonist at the human D3 receptor |
|
| DCC1444 | Cj2100 | Novel potent muscarinic antagonist wirh antimuscarinic antidepressant-like activities, showing modest affinity across the mAChRs when compared to L-687306 and scopolamine |
|
| DCC1445 | Cj-21058 | SecA inhibitor, showing antiprotozoal, antibacterial and antifungal effects, inhibiting post-translational protein transport into the endoplasmic reticulum. also Inhibiting ATP-dependant translocation of precursor proteins acrossing a bacterial cell membr |
|
| DCC1446 | Cj2-150 | Novel non-ATP competitive allosteric inhibitor of Aurora B kinase, binding in the allosteric site F |
|
| DCC1447 | Cj-3-60 | Anti-HIF-1alpha agent, inhibiting HIF-1alpha and cellular VEGF proteins |
|
| DCC1448 | Cj-887 Sodium Salt | Novel inhibitor of STAT3 activation and dimerization through targeting the phosphotyrosine binding site within the SH2 domain |
|
| DCC1449 | Cjc-1293 Tfa Salt | Stimulator of the production of growth hormone (GH) from the pituitary gland |
|
| DCC1450 | Cjc-1295 | Long-lasting stimulator of the production of growth hormone (GH) from the pituitary gland |
|
| DCC1451 | Ck2 Inhibitor Hy1 | Novel CK2 inhibitor, showing potent CSC inhibitory effects in A549 cells |
|
| DCC1452 | Ck-2-68 | Novel potent PfNDH2 inhibitor |
|
| DCC1453 | Ck2-in-27 | Novel selective allosteric modulator of the protein kinase CK2, inducing apoptosis and cell death in 786-O renal cell carcinoma cells (EC50 = 5 µM) and inhibiting STAT3 activation even more potently than the ATP-competitive drug candidate CX-4945 |
|
| DCC1454 | Ck2-in-3b | Potent, reversible, and ATP-competitive inhibitor of casein kinase-2 (CK2) |
|
| DCC1455 | Ck2-in-4p | Novel potent CK2 inhibitor |
|
| DCC1456 | Ck2-in-7 | Novel CK2 inhibitor, targeting an allosteric pocket, exhibiting an IC50 of 3.4 μM against purified CK2α in combination with a favorable selectivity profile |
|
| DCC1457 | Ck2-in-d11 | Novel potent and selective inhibitor of CK2. modulating the aforementioned signaling cascades and counteracting 17-AAG-mediated up-regulation of HSP70 in brain cancer cells |
|
| DCC1458 | ck2-in-tf | Novel cell-permeable and selective inhibitor of human protein kinase CK2, inducing apoptosis in the prostate cancer cell line LNCaP |
|
| DCC1459 | Ck2α-in-2 | Novel inhibitor of CK2α, binding in the ATP pocket |
|
| DCC1460 | Ckd712 | Inhibitor of vascular adhesion molecule-1 (VCAM-1), HMGB1 phosphorylation, iNOS expression, NFkB activation; Antiinflammatory |
|
| DCC1461 | Ckit-in-3 | Natural Dual Inhibitor for Wild Type and D816V Mutant of c-KIT Kinase |
|
| DCC1462 | Ckjb71 | Negative control for CK156 |
|
| DCC1463 | Cl-385319 | Inhibitor of H5N1 avian influenza A virus infection |
|
| DCC1464 | Cl387626 | Inhibitor of respiratory syncytial virus (RSV) |
|
| DCC1465 | Cx14442 Sodium | Novel potent inhibutor of HIV-1 integrase |
|
| DCC1466 | Claramine Tfa Salt | Novel protein tyrosine phosphatase-1B (PTP1B) inhibitor, neutralizing the toxicity of α-hemolysin, inhibiting β-secretase 1 (BACE1)-mediated insulin receptor cleavage |
|
| DCC1467 | Clathrin-in-25 | The most potent clathrin terminal domain-amphiphysin inhibitor reported to date |
|
| DCC1468 | Clathrodin | Natural modulator of voltage-gated sodium (NaV) channels |
|
| DCC1469 | C-laurdan | Novel two-photon polarity-sensitive lipid membrane probe |
|
